De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

ImpediMed Beheer

Beheer criteriumcontroles 1/4

De CEO ImpediMed's is Parmjot Bains, benoemd in Jan2024, heeft een ambtstermijn van minder dan een jaar. De totale jaarlijkse vergoeding van { bedraagt A$ 431.45K, bestaande uit 46.1% salaris en 53.9% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.001% van de aandelen van het bedrijf, ter waarde A$ 1.28K. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 0.8 jaar en 1.1 jaar.

Belangrijke informatie

Parmjot Bains

Algemeen directeur

AU$431.5k

Totale compensatie

Percentage CEO-salaris	46.1%
Dienstverband CEO	less than a year
Eigendom CEO	0.001%
Management gemiddelde ambtstermijn	less than a year
Gemiddelde ambtstermijn bestuur	1.1yrs

Recente managementupdates

Recent updates

Here's Why We're Not Too Worried About ImpediMed's (ASX:IPD) Cash Burn Situation

Sep 28

We're Not Worried About ImpediMed's (ASX:IPD) Cash Burn

Jun 10

A Look At The Fair Value Of ImpediMed Limited (ASX:IPD)

Feb 01

We Think ImpediMed (ASX:IPD) Can Afford To Drive Business Growth

Aug 25

Analyse CEO-vergoeding

Hoe is Parmjot Bains's beloning veranderd ten opzichte van ImpediMed's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jun 30 2024	AU$431k	AU$199k	-AU$20m

Compensatie versus markt: De totale vergoeding ($USD 297.76K ) Parmjot } is ongeveer het gemiddelde voor bedrijven van vergelijkbare omvang in de Australian markt ($USD 312.49K ).

Compensatie versus inkomsten: Er zijn onvoldoende gegevens om de beloning van Parmjot te vergelijken met de prestaties van het bedrijf.

CEO

Parmjot Bains

less than a year

Tenure

AU$431,451

Compensatie

Dr. Parmjot Bains, M.D. serves as Managing Director at ImpediMed Limited from January 08, 2023 and serves as its CEO since July 22, 2024 and serves as its Director from 2024 and served as its Chief Executi...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Parmjot Bains	MD, CEO & Director	less than a year	AU$431.45k	0.0011% A$ 1.3k
McGregor Grant	Chief Financial & Operating Officer and Executive Director	less than a year	AU$415.85k	0.10% A$ 119.2k
Andrew Grant	Executive Director and VP of Product Development & Customer Solutions	less than a year	AU$86.09k	0.099% A$ 116.0k
Dennis Schlaht	Senior Vice President of R&D and Technology	no data	AU$704.20k	geen gegevens
Tim Benkovic	Senior Vice President of Sales & Customer Success	less than a year	geen gegevens	geen gegevens
Ashley Munoz	Director of Human Resources	less than a year	geen gegevens	geen gegevens
Steven Chen	Chief Medical Center	1.1yrs	geen gegevens	geen gegevens
Leanne Ralph	Company Secretary	9.8yrs	geen gegevens	geen gegevens
Walton Taylor	Medical Director	14.6yrs	geen gegevens	geen gegevens

0.8yrs

Gemiddelde duur

Ervaren management: Het managementteam van IPD wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 0.8 jaar), wat duidt op een nieuw team.

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Parmjot Bains	MD, CEO & Director	less than a year	AU$431.45k	0.0011% A$ 1.3k
McGregor Grant	Chief Financial & Operating Officer and Executive Director	1.1yrs	AU$415.85k	0.10% A$ 119.2k
Andrew Grant	Executive Director and VP of Product Development & Customer Solutions	1.1yrs	AU$86.09k	0.099% A$ 116.0k
Christine Emmanuel-Donnelly	Independent Non-Executive Chair	1.1yrs	AU$116.97k	0.029% A$ 34.2k
Janelle Delaney	Independent Non-Executive Director	1.1yrs	AU$83.98k	0.19% A$ 227.9k
Fiona Bones	Non-Executive Director	less than a year	AU$6.64k	0.0040% A$ 4.6k

1.1yrs

Gemiddelde duur

Ervaren bestuur: De raad van bestuur van IPD wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 1.1 jaar), wat duidt op een nieuw bestuur.

ImpediMed Beheer

Beheer criteriumcontroles 1/4

Belangrijke informatie

Recente managementupdates

ImpediMed Limited, Annual General Meeting, Nov 19, 2024

Board Member recently bought AU$73k worth of stock

ImpediMed Limited Appoints Parmjot Bains as CEO on an ongoing basis

ImpediMed Limited Appoints Fiona Bones as A Non-Executive Director

Independent Non-Executive Director recently bought AU$50k worth of stock

Independent Non-Executive Director recently bought AU$100k worth of stock

Recent updates

ImpediMed Limited, Annual General Meeting, Nov 19, 2024

Price target decreased by 8.8% to AU$0.15

Consensus revenue estimates decrease by 14%

Board Member recently bought AU$73k worth of stock

Full year 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Forecast to breakeven in 2027

ImpediMed Limited to Report Fiscal Year 2024 Results on Aug 29, 2024

Forecast to breakeven in 2026

ImpediMed Limited Appoints Parmjot Bains as CEO on an ongoing basis

We Think ImpediMed (ASX:IPD) Can Afford To Drive Business Growth

ImpediMed Limited Appoints Fiona Bones as A Non-Executive Director

New minor risk - Market cap size

Independent Non-Executive Director recently bought AU$50k worth of stock

ImpediMed Limited to Report Q3, 2024 Results on Apr 30, 2024

Price target decreased by 9.6% to AU$0.18

ImpediMed to Present Chronic Breast Cancer-Related Lymphedema Study Results at American Society of Breast Surgeons Annual Meeting

Independent Non-Executive Director recently bought AU$100k worth of stock

ImpediMed (ASX:IPD) Is In A Good Position To Deliver On Growth Plans

Consensus revenue estimates decrease by 13%

Independent Non-Executive Director recently bought AU$90k worth of stock

Price target decreased by 12% to AU$0.19

No longer forecast to breakeven

High number of new and inexperienced directors

New minor risk - Share price stability

ImpediMed Limited to Report First Half, 2024 Results on Feb 27, 2024

Independent Non-Executive Director recently bought AU$135k worth of stock

Companies Like ImpediMed (ASX:IPD) Are In A Position To Invest In Growth

Consensus revenue estimates decrease by 20%

ImpediMed Limited Announces CFO Changes

Price target decreased by 16% to AU$0.23

Price target increased by 21% to AU$0.27

ImpediMed Limited to Report Q1, 2024 Results on Oct 31, 2023

ImpediMed Limited, Annual General Meeting, Nov 30, 2023

High number of new directors

ImpediMed Limited Announce the Appointment of Steven Chen as Chief Medical Officer

Consensus revenue estimates decrease by 23%

Full year 2023 earnings: EPS and revenues miss analyst expectations

Full year 2023 earnings: EPS and revenues miss analyst expectations

ImpediMed Limited, Annual General Meeting, Sep 28, 2023

Price target increased by 27% to AU$0.21

ImpediMed Limited to Report Q4, 2023 Results on Jul 24, 2023

Is ImpediMed (ASX:IPD) In A Good Position To Deliver On Growth Plans?

ImpediMed Limited Appoints Daniel Sharp as Director

Executive Director recently bought AU$144k worth of stock

Independent Non-Executive Chairman recently bought AU$82k worth of stock

No longer forecast to breakeven

MD, CEO & Director recently bought AU$52k worth of stock

MD, CEO & Director recently bought AU$54k worth of stock

Price target increased by 25% to AU$0.18

We Think ImpediMed (ASX:IPD) Needs To Drive Business Growth Carefully

MD, CEO & Director recently bought AU$64k worth of stock

First half 2023 earnings released: AU$0.01 loss per share (vs AU$0.006 loss in 1H 2022)

Price target decreased by 7.7% to AU$0.17

ImpediMed Limited to Report Q2, 2023 Results on Jan 30, 2023

ImpediMed Limited Presents New Data at 2022 San Antonio Breast Cancer Symposium Shows Early Detection Using L-Dex and Intervention Improves Lymphedema Progression-Free Survival

Impedimed Limited Announces CEO Changes

ImpediMed Limited Announces Management Changes

Less than half of directors are independent

Executive Director & Interim CEO recently bought AU$164k worth of stock

Less than half of directors are independent

ImpediMed Limited Announces Current Data Support Early Detection and Intervention to Reduce Rates of Breast Cancer Related Lymphedema

ImpediMed Limited to Report Q1, 2023 Results on Oct 19, 2022

ImpediMed Expands Use of SOZO in Leading Cancer Centers Focused on Reducing the Impact of Lymphedema after Breast Cancer

ImpediMed Announces U.S. Launch of Lymphedema Prevention Program with GenesisCare a Global Organization Dedicated to Care of Cancer Patients

Here's Why We're Not Too Worried About ImpediMed's (ASX:IPD) Cash Burn Situation

Consensus forecasts updated

Price target decreased to AU$0.18

ImpediMed Limited Announces Board Changes

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind